Cooccurrence of classic Hodgkin lymphoma and multiple myeloma

DOI Web Site PubMed
  • ANDOH Shohei
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • YOKOYAMA Kazuaki
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • UCHIDA Sanshiro
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • MAKIYAMA Junya
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • KAWAMATA Toyotaka
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • YASUI Hiroshi
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • OTA Yasunori
    Department of Pathology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • IMAI Yoichi
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo
  • TOJO Arinobu
    Department of Hematology/Oncology, Research Hospital, the Institute of Medical Science, the University of Tokyo

Bibliographic Information

Other Title
  • 古典的ホジキンリンパ腫診断時に合併を認めた多発性骨髄腫
  • コテンテキ ホジキン リンパシュ シンダンジ ニ ガッペイ オ ミトメタ タハツセイ コツズイシュ

Search this article

Abstract

<p>Although classic Hodgkin’s lymphoma (CHL) sometimes develops after treatment for multiple myeloma (MM), simultaneous diagnosis of both malignancies is extremely rare without previous treatment history. Here we describe a case of a 54-year-old female who complained of left cervical lymphadenopathy. Biopsy specimen from the left cervical lymph node revealed mixed-cellularity CHL. Bone marrow aspirate comprised 10.3% plasma cells. She was diagnosed with MM due to involved: uninvolved serum free light chain ratio of >100. She achieved complete response for CHL after 4 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy along with 30 Gy of involved-field radiotherapy. Three years later, bortezomib, lenalidomide, and dexamethasone (VRd-lite) therapy was initiated for MM. Severe neutropenia during her 1st cycle prompted a dosage reduction of lenalidomide and bortezomib. Partial response was achieved after 4 cycles of VRd-lite followed by high-dose melphalan/autologous stem cell transplantation. No severe adverse events were recorded. This was followed by 4 cycles of carfilzomib, lenalidomide, and dexamethasone therapy, which resulted in complete remission. As the number of elderly people increases, multiple myeloma patients with previous history of other malignancies would increase. Our case has shown that VRd-lite therapy may be suitable for those patients.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 62 (1), 14-19, 2021

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top